Author:
Schlindwein Walkiria,Bezerra Mariana,Almeida Juan,Berghaus Andreas,Owen Martin,Muirhead Gordon
Abstract
This paper displays the potential of an in-line PAT system for early phase product development during pharmaceutical continuous manufacturing following a Quality by Design (QbD) framework. Hot melt extrusion (HME) is used as continuous manufacturing process and UV–Vis spectroscopy as an in-line monitoring system. A sequential design of experiments (DoE) (screening, optimisation and verification) was used to gain process understanding for the manufacture of piroxicam (PRX)/Kollidon® VA64 amorphous solid dispersions. The influence of die temperature, screw speed, solid feed rate and PRX concentration on the critical quality attributes (CQAs) absorbance and lightness of color (L*) of the extrudates was investigated using multivariate tools. Statistical analysis results show interaction effects between concentration and temperature on absorbance and L* values. Solid feed rate has a significant effect on absorbance only and screw speed showed least impact on both responses for the screening design. The optimum HME process conditions were confirmed by 4 independent studies to be 20% w/w of PRX, temperature 140 °C, screw speed 200 rpm and feed rate 6 g/min. The in-line UV-Vis system was used to assess the solubility of PRX in Kollidon® VA64 by measuring absorbance and L* values from 230 to 700 nm. Oversaturation was observed for PRX concentrations higher than 20% w/w. Oversaturation can be readily identified as it causes scattering in the visible range. This is observed by a shift of the baseline in the visible part of the spectrum. Extrudate samples were analyzed for degradation using off-line High-Performance Liquid Chromatography (HPLC) standard methods. Results from off-line experiments using differential scanning calorimetry (DSC), and X-ray diffraction (XRD) are also presented.
Reference53 articles.
1. Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving From Theory to Practice
2. U.S. Food and Drug Administration Approves ORKAMBI® (Lumacaftor/Ivacaftor) 2016https://investors.vrtx.com/news-releases/news-release-details/us-food-and-drug-administration-approves-orkambir
3. FDA Approves Tablet Production on Janssen Continuous Manufacturing Line 2016http://www.pharmtech.com/fda-approves-tablet-production-janssen-continuous-manufacturing-line
4. Continuous manufacturing via hot-melt extrusion and scale up: regulatory matters
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献